1
|
Biesma H, Soeratram A, Sikorska K, Caspers I, van Essen H, Egthuijsen J, Mookhoek A, Hoek D, Vos W, van Laarhoven H, Nordsmark M, van der Peet D, Warmerdam F, Geenen M, Loosveld O, Portielje J, Los M, Kranenbarg EMK, Hartgrink H, van Sandick J, van de Velde C, Verheij M, Cats A, Ylstra B, van Grieken N. Abstract 354: Mucinous phenotype is associated with response to neoadjuvant chemotherapy in microsatellite instable resectable gastric cancer. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Epstein-Barr virus positivity (EBV+) and microsatellite instability (MSI-high) have been shown to be positive prognostic factors for long term survival in resectable gastric cancer (GC) in several studies. However, the benefit of perioperative treatment in patients with MSI-high tumors remains topic of discussion. Here, we present the clinicopathological outcome of patients with EBV+ and MSI-high GCs treated with surgery only in the Dutch D1/D2 trial, and treated with chemotherapy or chemoradiotherapy after preoperative chemotherapy and surgery in the CRITICS trial.
Patients and methods: EBV was determined in tumor tissue using EBV-encoded RNA in situ hybridization (EBER-ISH). PCR and/or immunohistochemistry were performed to determine MSI status. Results were correlated to histopathological response, morphological tumor characteristics and survival.
Results: In the Dutch D1/D2 trial 10.5% (47/447) of tumors were EBV+ and 10.5% (47/447) were MSI-high. In the CRITICS trial 5.5% (25/451) of tumors were EBV+ and 5.5% (25/451) were MSI-high tumors. In the Dutch D1/D2 trial, five-year overall survival probability was 51.1% for EBV+, 46.8% for MSI-high, and 42.5% for EBV-/MSS (P=0.19). In the CRITICS trial, five-year overall survival was 56.0% for EBV+, 47.3% for MSI-high, and 36.5% for EBV-/MSS (P=0.22). In the CRITICS trial, 3 (12.5%) MSI-high tumors showed moderate to complete histopathological response. Interestingly, all three showed a mucinous phenotype. Eight (36.4%) EBV+ and 114 (29.9%) EBV-/MSS tumors showed moderate to complete histopathological response. None of the EBV+ GCs showed mucinous differentiation.
Conclusions: The favorable outcome of GC patients with resectable EBV+ or MSI-high tumors compared to EBV-/MSS tumors remains after perioperative chemotherapy. In MSI-high tumors significant histopathological response to neoadjuvant chemotherapy was found only in those with a mucinous phenotype.
Citation Format: H.D. Biesma, A.T.T.D. Soeratram, K. Sikorska, I.A. Caspers, H.F. van Essen, J.M.P. Egthuijsen, A. Mookhoek, D.M. Hoek, W. Vos, H.W.M. van Laarhoven, M. Nordsmark, D.L. van der Peet, F.A.R.M. Warmerdam, M.M. Geenen, O.J.L. Loosveld, J.E.A. Portielje, M. Los, E. Meershoek - Klein Kranenbarg, H.H. Hartgrink, J. van Sandick, C.J.H. van de Velde, M. Verheij, A. Cats, B. Ylstra, N.C.T. van Grieken, On behalf of the CRITICS investigators. Mucinous phenotype is associated with response to neoadjuvant chemotherapy in microsatellite instable resectable gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 354.
Collapse
Affiliation(s)
- H.D. Biesma
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | | | - K. Sikorska
- 2Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - I.A. Caspers
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - H.F. van Essen
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | | | - A. Mookhoek
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - D.M. Hoek
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - W. Vos
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | | | | | | | | | | | | | | | - M. Los
- 8St. Antonius Hospital, Nieuwegein, Netherlands
| | | | | | - J. van Sandick
- 2Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | | | - M. Verheij
- 10Radboud University Medical Center, Nijmegen, Netherlands
| | - A. Cats
- 2Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - B. Ylstra
- 1Amsterdam University Medical Centers, Amsterdam, Netherlands
| | | | | |
Collapse
|
2
|
De Voogd FA, Mookhoek A, Gecse KB, De Hertogh G, Bemelman WA, Buskens CJ, D'Haens GR. Systematic Review: Histological Scoring of Strictures in Crohn's Disease. J Crohns Colitis 2020; 14:734-742. [PMID: 32645156 DOI: 10.1093/ecco-jcc/jjz177] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND AIMS In Crohn's disease, many patients develop a stricture, which can due to inflammation, fibrosis and muscular changes or all at the same time. Determining the predominant component has therapeutic consequences but remains challenging. To develop imaging techniques that assess the nature of a stricture, a gold standard is needed and histopathology is considered as such. This paper provides an overview of published histological scoring systems for strictures in Crohn's disease. METHODS A systematic literature review according to PRISMA guidelines was performed of histological scoring indices that assessed whether a stricture was inflammation-predominant or fibrosis-predominant. Multiple libraries were searched from inception to December 2018. Two reviewers independently assessed abstracts and full-texts. RESULTS Sixteen articles were identified as suitable for this systematic review. A large number of parameters were reported. Extent of neutrophil infiltration and extent of fibrosis in the bowel wall were most frequently described to reflect severity of inflammation and fibrosis, respectively. Among the 16 studies, only two described a numerical scoring system for the inflammatory and fibrotic component separately. Smooth muscle changes were scored in a minority of studies. CONCLUSIONS Multiple scoring systems have been developed. There was large heterogeneity in scoring per parameter and construction of numerical scoring systems. Therefore, we feel that none of the systems is suitable to be used as gold standard. We offer an overview of histological parameters that could be incorporated in a future histological scoring index for strictures.
Collapse
Affiliation(s)
- F A De Voogd
- Amsterdam UMC, Amsterdam Medical Center, University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands
| | - A Mookhoek
- Amsterdam UMC, VU Medical Center, VU University, Department of Pathology, Amsterdam, The Netherlands
| | - K B Gecse
- Amsterdam UMC, Amsterdam Medical Center, University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands
| | - G De Hertogh
- University Hospitals Leuven, University of Leuven, Department of Pathology, Leuven, Belgium
| | - W A Bemelman
- Amsterdam UMC, Amsterdam Medical Center, University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands
| | - C J Buskens
- Amsterdam UMC, Amsterdam Medical Center, University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands
| | - G R D'Haens
- Amsterdam UMC, Amsterdam Medical Center, University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands
| |
Collapse
|